Recombinant Humanized (from mouse) antibody to Human PCSK9. Bococizumab (codenamed RN316)is a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
Figure 1 Effect of Antidrug Antibodies on the Durability of Low-Density Lipoprotein (LDL) Cholesterol Lowering and on Plasma Bococizumab and PCSK9 Levels.
Panel A shows the effect of generalized antidrug antibodies (ADAs) on LDL cholesterol levels among the patients who received placebo and among those who received bococizumab, according to whether the patients were ADA-negative throughout the trial, had ADA titers in the lowest two thirds of maximum titers (<1:1176) during follow-up, had ADA titers in the highest third of titers (≥1:1176) during follow-up, or were in the subgroup with ADA titers in the top 10% (≥1:5674). The light blue bars indicate prevalent rates of antibodies at each time point, and the dark blue bars the cumulative incidence of antibody positivity during follow-up. Panel B shows plasma bococizumab levels and Panel C total plasma proprotein convertase subtilisin–kexin type 9 (PCSK9) levels over time, according to the ADA titer. Panel D shows the effect of the neutralizing antibody (NAb) titer on LDL cholesterol levels.
Figure 2 Variability in the Reduction in LDL Cholesterol Levels, According to the Presence or Absence of Antidrug Antibodies (ADAs).
Waterfall plots for individual patients who received bococizumab show the percent change from baseline in LDL cholesterol levels at 12 weeks (Panel A) and at 52 weeks among the patients in whom antidrug antibodies developed (Panel B) and among those in whom antidrug antibodies did not develop (Panel C). Data are limited to the patients who reported having received bococizumab in the 21 days before the measurement of LDL cholesterol.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Bococizumab.
Afuco™ Anti-PCSK9 ADCC Therapeutic Antibody (Bococizumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human PCSK9. Bococizumab (codenamed RN316)is a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
For Research Use Only. Not For Clinical Use.